SCHEMBL25286268

SCHEMBL25286268

COc1cc(Cl)cc2[nH]c(C(=O)NC(C[Si](C)(C)C)C(=O)OC(C)(C)C)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.43
▸ CTSB P07858 1/20 0.43
▸ CTSS P25774 1/20 0.43
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ RCE1 Q9Y256 1/20 0.38
▸ PYGL P06737 1/20 0.38
▸ RHEB Q15382 3/20 0.37
▸ CTNNB1 P35222 1/20 0.37
▸ ALOX15 P16050 1/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC10 Q969S8 1/20 0.36
▸ HDAC11 Q96DB2 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC9 Q9UKV0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30310512 1.00 CTSL (0.43) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL24113461 1.00 CTSL (0.43) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL25287894 0.87 CTSL (0.48) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL30310357 0.87 CTSL (0.48) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL24113462 0.87 CTSL (0.48) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL29062712 0.85 KMT2A (0.55) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL30310653 0.85 KMT2A (0.55) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL24113471 0.85 KMT2A (0.55) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL24739966 0.78 ALOX15 (0.58) CTSLCTSBCTSSKMT2AMEN1
SCHEMBL23824623 0.73 MEN1 (0.59) CTSLCTSBCTSSKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 — — CN disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV CTSL 2/4885CTSB 27/4885CTSS 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback